Market Research Report: SELLAS Life Sciences Group

Company Overview

Name and Mission

Name: SELLAS Life Sciences Group
Mission: SELLAS Life Sciences is a late-stage clinical biopharmaceutical company dedicated to the development of novel therapeutics for a wide range of cancer indications.

Founding Details

Founded: No specific information on the founding date or founders is available.

Key People

• Angelos M. Stergiou, M.D., Sc.D. h.c. - President and Chief Executive Officer

• Dragan Cicic, M.D. - Senior Vice President, Chief Development Officer

• John T. Burns, C.P.A. - Senior Vice President, Chief Financial Officer

• Andrew Elnatan - Vice President, Regulatory Affairs, CMC & Quality

• Stacy E. Yeung - Vice President, Associate General Counsel & Head of Compliance

Headquarters

Location: 7 Times Square, Suite 2503, New York, NY 10036

Employees

No information is available regarding the number of employees.

Revenue

No information is available regarding the company's revenue.

Company Reputation

Known For: SELLAS Life Sciences is known for developing cancer therapeutics, currently focusing on product candidates like galinpepimut-S (GPS) and SLS009.

Products

Galinpepimut-S (GPS)

• Description: A WT1-targeting cancer immunotherapeutic agent.

• Key Features:

• Targets the WT1 protein, significant in numerous cancer types.

• Licensed globally from Memorial Sloan Kettering Cancer Center.

• Undergoing Phase 3 trials for conditions like Acute Myeloid Leukemia (AML).

SLS009

• Description: A highly selective small molecule CDK9 inhibitor.

• Key Features:

• Potential to be the first and best-in-class with reduced toxicity.

• Licensed for use outside of Greater China from GenFleet Therapeutics (Shanghai), Inc.

Recent Developments

New Product Launches and Developments

• Galinpepimut-S (GPS): Received FDA Rare Pediatric Disease Designation for the treatment of pediatric acute myeloid leukemia. It is currently being investigated in a Phase 3 REGAL Trial for adult AML patients.

• SLS009: Granted EMA Orphan Drug Designation for the treatment of Peripheral T-Cell Lymphomas.

New Features

No information is available regarding new features added to existing products.

Partnerships

1. Memorial Sloan Kettering Cancer Center: Exclusive global collaboration and license agreement related to WT1 cancer immunotherapy.
2. 3D Medicines, Inc.: Exclusive license agreement for development and commercialization in Greater China.
3. GenFleet Therapeutics (Shanghai), Inc.: Exclusive license agreement for CDK9 inhibitor development outside Greater China.

Corporate Events

• Participated in the 2024 Maxim Healthcare Virtual Summit on October 10, 2024.

• Reported a financial update on August 13, 2024, including a recommendation to continue the Phase 3 REGAL Study based on positive preliminary data.

Conclusion

This report offers a detailed overview of SELLAS Life Sciences Group, focusing on its cancer therapeutics, particularly its innovative GPS and SLS009 products, and its recent strategic developments and partnerships to enhance its market position in biopharmaceutical innovations.